12.82
price down icon0.70%   -0.09
after-market 시간 외 거래: 12.82
loading
전일 마감가:
$12.91
열려 있는:
$12.91
하루 거래량:
378.42K
Relative Volume:
0.90
시가총액:
$298.32M
수익:
$157.75M
순이익/손실:
$-29.73M
주가수익비율:
-11.05
EPS:
-1.16
순현금흐름:
$-21.00M
1주 성능:
+16.55%
1개월 성능:
+10.71%
6개월 성능:
-34.49%
1년 성능:
-51.71%
1일 변동 폭
Value
$12.25
$13.20
1주일 범위
Value
$11.13
$13.66
52주 변동 폭
Value
$8.04
$45.00

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Name
명칭
Arcturus Therapeutics Holdings Inc
Name
전화
(858) 900-2660
Name
주소
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Name
직원
176
Name
트위터
@ArcturusRx
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
ARCT's Discussions on Twitter

ARCT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ARCT
Arcturus Therapeutics Holdings Inc
12.82 298.32M 157.75M -29.73M -21.00M -1.16
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
496.49 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.86 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
620.97 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
254.85 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.46 24.70B 3.81B -644.79M -669.77M -6.24

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-28 개시 BTIG Research Buy
2024-08-12 개시 Leerink Partners Outperform
2023-12-13 개시 Canaccord Genuity Buy
2023-07-24 개시 William Blair Outperform
2023-05-11 업그레이드 H.C. Wainwright Neutral → Buy
2022-11-14 재개 Wells Fargo Overweight
2022-11-10 다운그레이드 Robert W. Baird Neutral → Underperform
2022-11-03 업그레이드 Citigroup Neutral → Buy
2022-11-02 업그레이드 Barclays Underweight → Equal Weight
2022-08-10 다운그레이드 Raymond James Mkt Perform → Underperform
2022-07-19 재개 Cantor Fitzgerald Overweight
2022-05-11 업그레이드 Robert W. Baird Underperform → Neutral
2022-04-21 다운그레이드 Citigroup Buy → Neutral
2022-01-31 업그레이드 Raymond James Underperform → Mkt Perform
2021-08-12 다운그레이드 Raymond James Mkt Perform → Underperform
2021-08-11 다운그레이드 Goldman Neutral → Sell
2021-08-10 다운그레이드 Robert W. Baird Neutral → Underperform
2021-07-02 개시 Cantor Fitzgerald Overweight
2021-06-25 재개 Goldman Neutral
2021-06-21 다운그레이드 Barclays Equal Weight → Underweight
2021-06-04 재개 Robert W. Baird Neutral
2021-02-17 다운그레이드 B. Riley Securities Neutral → Sell
2021-01-19 다운그레이드 B. Riley Securities Buy → Neutral
2021-01-15 다운그레이드 B. Riley Securities Buy → Neutral
2021-01-07 개시 Wells Fargo Overweight
2020-12-29 다운그레이드 Barclays Overweight → Equal Weight
2020-12-29 다운그레이드 H.C. Wainwright Buy → Neutral
2020-12-29 다운그레이드 Raymond James Outperform → Mkt Perform
2020-12-29 다운그레이드 Robert W. Baird Outperform → Neutral
2020-12-23 다운그레이드 ROTH Capital Buy → Sell
2020-12-08 재확인 B. Riley Securities Buy
2020-12-07 재확인 B. Riley Securities Buy
2020-10-26 개시 Barclays Overweight
2020-10-06 개시 Citigroup Buy
2020-08-26 개시 Piper Sandler Overweight
2020-07-30 재개 ROTH Capital Buy
2020-07-16 개시 Raymond James Outperform
2020-07-13 개시 B. Riley FBR Buy
2020-06-09 다운그레이드 WBB Securities Buy → Hold
2020-02-11 개시 Robert W. Baird Outperform
2020-02-07 개시 Guggenheim Buy
2020-02-06 개시 Guggenheim Buy
2019-04-05 개시 H.C. Wainwright Buy
2018-09-20 업그레이드 WBB Securities Buy → Strong Buy
2018-01-22 개시 Chardan Capital Markets Buy
모두보기

Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스

pulisher
Apr 24, 2025

Geode Capital Management LLC Has $9.42 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress - ADVFN

Apr 23, 2025
pulisher
Apr 22, 2025

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025 - Business Wire

Apr 22, 2025
pulisher
Apr 22, 2025

Long Term Trading Analysis for (ARCT) - news.stocktradersdaily.com

Apr 22, 2025
pulisher
Apr 21, 2025

JPMorgan Chase & Co. Has $4.01 Million Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 21, 2025
pulisher
Apr 20, 2025

Research Analysts Set Expectations for ARCT Q1 Earnings - American Banking and Market News

Apr 20, 2025
pulisher
Apr 19, 2025

Q1 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine (PR Newswire) - Aktiellt

Apr 18, 2025
pulisher
Apr 15, 2025

Vanguard Group Inc. Grows Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 15, 2025
pulisher
Apr 14, 2025

Can The Upcoming Catalysts Breathe New Life Into Arcturus Therapeutics? - RTTNews

Apr 14, 2025
pulisher
Apr 13, 2025

Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate - MSN

Apr 13, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Acquires New Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World

Apr 12, 2025
pulisher
Apr 11, 2025

High Growth Tech Stocks To Watch In The US April 2025 - simplywall.st

Apr 11, 2025
pulisher
Apr 11, 2025

Arcturus Therapeutics (ARCT) Gains FDA Fast Track for Influenza Vaccine - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Arcturus Therapeutics (ARCT) Receives Fast Track Status for Infl - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation f - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim Lowers Price Target for Arcturus Therapeutics (ARCT) Amid Risk Adjustments | ARCT Stock News - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Arcturus wins FDA fast track status for influenza vaccine - MSN

Apr 10, 2025
pulisher
Apr 10, 2025

Arcturus wins FDA fast track status for flu shot (ARCT:NASDAQ) - Seeking Alpha

Apr 10, 2025
pulisher
Apr 10, 2025

Arcturus Therapeutics Says FDA Granted Fast Track Designation to Potential H5N1 Vaccine - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1 - Business Wire

Apr 10, 2025
pulisher
Apr 10, 2025

Breakthrough: FDA Fast-Tracks Revolutionary mRNA Vaccine Against Deadly H5N1 Pandemic Flu - Stock Titan

Apr 10, 2025
pulisher
Apr 09, 2025

Commonwealth Equity Services LLC Reduces Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Apr 09, 2025
pulisher
Apr 07, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $59.20 Consensus Price Target from Brokerages - Defense World

Apr 07, 2025
pulisher
Apr 06, 2025

(ARCT) Investment Report - news.stocktradersdaily.com

Apr 06, 2025
pulisher
Mar 26, 2025

(ARCT) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Mar 26, 2025
pulisher
Mar 24, 2025

Bank of New York Mellon Corp Sells 22,024 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World

Mar 24, 2025
pulisher
Mar 20, 2025

Is Arcturus Therapeutics (ARCT) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey

Mar 20, 2025
pulisher
Mar 20, 2025

Benign Growth For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Underpins Stock's 26% Plummet - simplywall.st

Mar 20, 2025
pulisher
Mar 18, 2025

Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN

Mar 18, 2025
pulisher
Mar 17, 2025

William Blair Issues Pessimistic Outlook for ARCT Earnings - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

(ARCT) Proactive Strategies - news.stocktradersdaily.com

Mar 16, 2025
pulisher
Mar 13, 2025

Arcturus Therapeutics Holdings Inc to Host Earnings Call - ACCESS Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $61.40 Average PT from Analysts - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Arcturus Therapeutics at Leerink’s Conference: mRNA Innovations and Strategic Plans - Investing.com UK

Mar 12, 2025
pulisher
Mar 12, 2025

Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism - markets.businessinsider.com

Mar 12, 2025
pulisher
Mar 11, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Given New $68.00 Price Target at Canaccord Genuity Group - Defense World

Mar 11, 2025
pulisher
Mar 09, 2025

Analysts Have Lowered Expectations For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) After Its Latest Results - Simply Wall St

Mar 09, 2025
pulisher
Mar 09, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo

Mar 09, 2025
pulisher
Mar 09, 2025

HC Wainwright Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $60.00 - Defense World

Mar 09, 2025
pulisher
Mar 09, 2025

Arcturus Therapeutics (NASDAQ:ARCT) Earns Overweight Rating from Cantor Fitzgerald - Defense World

Mar 09, 2025
pulisher
Mar 08, 2025

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 08, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 By Investing.com - Investing.com Australia

Mar 07, 2025
pulisher
Mar 07, 2025

Beyond The Numbers: 8 Analysts Discuss Arcturus Therapeutics Stock - Benzinga

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics stock hits 52-week low at $14.3 - Investing.com India

Mar 07, 2025
pulisher
Mar 07, 2025

Earnings call transcript: Arcturus Therapeutics Q4 2024 misses estimates By Investing.com - Investing.com South Africa

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Reports Q4 2024 Earnings: EPS of ($1.11) M - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... - Yahoo Finance

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call - GuruFocus.com

Mar 07, 2025
pulisher
Mar 07, 2025

Arcturus Therapeutics Holdings Inc (ARCT) Q4 2024 Earnings Call Highlights: Navigating ... By GuruFocus - Investing.com Canada

Mar 07, 2025

Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.63
price up icon 0.19%
$69.86
price up icon 0.24%
$32.54
price up icon 1.06%
$24.11
price up icon 2.75%
$104.00
price up icon 1.94%
biotechnology ONC
$249.46
price up icon 1.86%
자본화:     |  볼륨(24시간):